Corrigendum: Clinical efficacy, safety and tolerability of a new subcutaneous immunoglobulin 16.5% (Octanorm [Cutaquig^®]) in the treatment of patients with primary immunodeficiencies

Affiliations

• ¹ UCLA School of Medicine, Los Angeles, CA, United States.
• ² Division of Basic and Clinical Immunology, University of California, Irvine, Irvine, CA, United States.
• ³ IMMUNOe Research Center, Centennial, CO, United States.
• ⁴ Pediatric Pulmonary Associates of North Texas, Frisco, TX, United States.
• ⁵ Midlands Pediatrics, Papillion, NE, United States.
• ⁶ Divisionof Hematology, Department of Medicine, University of Alberta Hospital, Edmonton, AB, Canada.
• ⁷ Divisions of Adult and Pediatric Allergy and Immunology, University of California, San Diego, La Jolla, CA, United States.
• ⁸ Department of Pediatric Allergy, Asthma and Immunology, University of Alabama, Birmingham, AL, United States.
• ⁹ Allergy and Asthma Center Inc., Toledo, OH, United States.
• ¹⁰ Octapharma Pharmazeutika Produktionsges.m.b.H., Vienna, Austria.
• ¹¹ Department of Clinical Immunology and Allergology, St Anne's University Hospital in Brno, Faculty of Medicine, Masaryk University, Brno, Czechia.